Global Bio-pharmaceuticals Market Projected to $225.9 Billion by 2018

Date: 2016-09-11

Bio-pharmaceuticals are medicinal drugs which are produced through biotechnology methods such as recombinant DNA techniques, fermentation, hybridoma techniques, and purification processes. Bio-pharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments. Various Bio-pharmaceuticals used for treating such diseases are monoclonal antibodies, erythropoietin, growth hormones, recombinant proteins, recombinant human insulin, purified proteins, interferon, vaccines and other Bio-pharmaceuticals. However, high costs of Bio-pharmaceuticals, entry of low-cost biosimilars, and risk of side-effects posed by Bio-pharmaceuticals act as restraints for the Bio-pharmaceuticals market.

According to the statistics, the global bio-pharmaceuticals market reached USD 176.5 billion in 2015, and is projected to reach over USD 225.9 billion by 2018, at a CAGR of approximately 9.0% from 2016 to 2018.

The North America is the largest market for bio-pharmaceuticals, it occupied about 40% of global bio-pharmaceuticals market, followed by Europe.

Some of the leading players in the global market for biopharmaceuticals include Roche (Switzerland), Pfizer Inc. (USA), Johnson & Johnson Services, Inc. (USA), Sanofi (France), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Merck & Co. (U.S.), Biogen Idec (U.S.), Bayer AG (Germany), Eli Lilly and Company (USA) etc..

Global Bio-pharmaceuticals Market Share, by region, 2020


Read Full Report:

Joanna | Executive – International Business and partner Relations
E-mail: | Tel: 1-510-400-8520


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample